Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.

3 Reasons to Watch MRNA

• That 13% Friday Pop Needs Explaining. Moderna closed out last week as one of the S&P 500's top performers, ripping more than 12% in a single session on renewed excitement around its cancer pipeline and a push into CAR-T cell therapy. When markets reopen Monday, watch to see whether that momentum holds or whether traders use the opening pop as a chance to take profits after a 34% run in just 30 days.
• The Oncology Story Is Getting Real Attention. The Friday surge wasn't just about COVID boosters — the catalyst driving optimism is Moderna's expanding oncology pipeline, including personalized cancer therapy and cell therapy enhancers that represent a completely different revenue story than vaccines. If that narrative continues to gain traction heading into the week, the stock could start attracting a new class of growth-oriented biotech buyers who previously dismissed Moderna as a one-trick pandemic play.
• Healthcare Is Catching a Rotation Tailwind. Investors pulling money out of tech are increasingly parking it in healthcare names, and Moderna sits right at the intersection of that rotation given its biotech profile and pipeline breadth. That macro shift could provide a meaningful floor for MRNA even on days when company-specific news is quiet, so keep an eye on how the broader healthcare sector trades Monday morning as a read on whether this tailwind has staying power.

Top Market Headlines

AI Data Centers Will Consume 70% of All Memory Chips in 2026. Here Are the Only 2 Stocks That Matter.

Most of the memory now being produced is going into AI data centers, leading to tight supplies for other uses.

The verdict is in for AI stocks in 2026 (Ad)

Move your money out of overpriced AI stocks before the tech trade breaks down in 2026. Get into these smaller, lesser-known names that are showing the potential to dethrone the Mag 7 in 2026. Make sure three alternatives to Nvidia, Tesla, and Amazon are on your radar before markets open tomorrow.

2 Blue Chip Industrial Stocks I'd Buy Into This Week's Weakness Without Hesitation

Canadian National Railway could see volume rebound in the second half of 2026. Johnson Controls offers investors an industrial play on data centers.

Everyone Is Talking About SpaceX. Here Are 2 Growth Stocks I Like Much Better.

MercadoLibre is several decades old and still growing like a start-up. On Holding is building its brand as a premium, full-priced athleticwear giant.

How to tap into SpaceX IPO - without buying a single share (Ad)

Would you like to know how to tap into the SpaceX IPO windfall ... Without buying a single share? This has nothing to do with options, ETFs, or anything like that. Best of all, anybody can learn how to do it.

Micron's Blockbuster, AI

The rally for memory stocks is back on, with Micron leading the way.

Try out Musk's new AI agent – before his big announcement (Ad)

Elon just created a device he believes will be "the biggest product ever." He thinks it could 70x investors' money. And he's about to make a major announcement… By the end of this month. Maybe even tomorrow on X. He's going to make this game-changing device available to the public for the first time. He has to sell 1 million to become a trillionaire. Would you bet against him?